COVID-19 DIAGNOSTICS ________
LATERAL FLOW ANTIGEN TESTING
Prognosis Biotech has developed the Rapid Test Ag 2019-nCov kits for the detection of SARS-CoV-2 antigen (nucleocapsid protein) in nasopharyngeal & nasal swab specimens.
This test is designed to rapidly identify infected individuals, enabling prompt clinical decisions and preventing potential virus outbreaks.
The Rapid Test Ag 2019-nCov does not require any special instrument or skill set and can be used in all types of premises where COVID-19 testing is required.
RAPID TEST ________
SARS-CoV-2 & INFLUENZA A_B
As the world faces each new variant of COVID-19, the flu season across many parts of the world makes the fight against the pandemic even harder.
Prognosis Biotech has developed a new assay that allows medical professionals to provide rapid point-of-care testing and results for SARS-CoV-2 and Influenza A and B, from the same specimen. With this Rapid Test the cause of flu-like symptoms can be identified, giving the answer to one of the most important questions nowadays, “Is it COVID-19 or just the flu?”.
The new Rapid Test FLU_COVID offers a simplistic collection and streamlined testing process to deliver 3 results in 15 minutes.
RAPID TEST ________
INFLUENZA A_B
Seasonal flu cases are caused by the two main types of influenza, A and B, and account for millions of cases worldwide. Flu-related complications occur, raising the number of hospitalizations of those who are considered “at-risk”.
Accurate detection and diagnosis of the flu, within a few days of the symptom’s onset, is crucial for patients in order to begin treatment. The Prognosis Biotech Rapid Test FLU A_B is designed using novel and rapid immunoassay technology, which offers fast and reliable results, allowing health care providers to confidently use it in a point-of-care setting.
rapid test ________
ADENOVIRUS
Adenoviruses are common in humans, usually cause respiratory illness while also being responsible for gastroenteritis, conjunctivitis, cystitis. Symptoms of respiratory illness range from the common cold syndrome to pneumonia, affect all ages and do not show seasonal infection. Most serious infections occur in individuals who are immunocompromised and young children.
The Prognosis Biotech Rapid Test Adenovirus is a qualitative immunoassay kit that helps laboratories and physicians detect the adenovirus antigen and confirm the diagnosis of adenovirus in patients with a respiratory illness.
rapid test ________
RESPIRATORY SYNCYTIAL VIRUS (RSV)
Respiratory syncytial virus or RSV is a common and very contagious virus, that infects the respiratory tract. It is so common that most children have been infected with the virus by the age of two. In most cases it causes mild, cold-like symptoms, but for a small percentage, infection with RSV can lead to serious, sometimes life-threatening problems. Babies, young children, anyone with a weakened immune system and older adults are at greatest risk of severe infection.
The Prognosis Biotech Rapid Test RSV is an immunoassay kit that helps medical professionals detect the RSV protein and reach a quick diagnosis.
COVID-19 DIAGNOSTICS ________
LATERAL FLOW & ELISA ANTIBODY TESTING
Prognosis Biotech has developed the Rapid Test 2019-nCov Total Ig kits for the detection of SARS-CoV-2 Immunoglobulin antibodies in blood specimens.
This test is designed to detect a body’s immune response to SARS-CoV-2 (i.e., a past infection, not active infection) and comes in two different formats for application:
ELISA (Enzyme-linked immunosorbent assay) format made for testing laboratories. The following kits are available:
– Bio-Shield 2019-nCoV Total Immunoglobulins (IgA, IgG, IgM)
– Bio-Shield 2019-nCoV IgG
– Bio-Shield 2019-nCoV IgM
– Bio-Shield 2019-nCoV IgA
Rapid Lateral Flow format: an easy-to-use device with increased sensitivity that does not require any special instrument or skill set and can be used in all types of premises where COVID-19 testing is required.
COVID-19 DIAGNOSTICS ________
LATERAL FLOW ANTIGEN TESTING FOR SURFACES
The Rapid Surface Ag 2019-nCov is a rapid test for the detection of SARS-CoV-2 Nucleocapsid Protein Antigen (NP) in swabs of common surfaces, such as metal, plastic, glass, paper, and stainless steel. It is the first product for COVID-19 surface testing to utilize this innovative methodology.
The Rapid Surface Ag 2019-nCov is a valuable tool for several sectors enabling the companies to monitor and mitigate the spread of COVID-19 in their facilities and maintain a safe operating environment.